Name: 글로벌 시장 동향
SKU: PH1542
Availability: InStock

보고서 요약(국문)

개요
글로벌 치료용 백신 시장은 2022년 YY백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.
치료용 백신은 감염 후 항바이러스 면역을 유도하여 질병의 경과를 바꾸는 백신입니다. 궁극적인 목표는 숙주 면역 체계를 변화시켜 질병을 퇴치하고 장기적인 면역 기억을 형성하는 것입니다.
나노생명공학의 급속한 발전은 치료용 암 백신 개발에 진전을 가져왔습니다. 치료용 암 백신의 주요 목적은 살해 T세포 활성화를 포함한 세포 면역 반응을 유도하는 것입니다.
시장 동향: 동인 및 제약 요인
감염성 질환의 증가
감염성 질환의 증가는 많은 사람들의 삶에 영향을 미치고 있습니다. 감염 예방을 위해 여러 가지 새로운 치료용 백신이 개발되었습니다. 치료용 백신의 혁신 증가는 시장 성장을 견인할 것으로 예상됩니다.

예를 들어, 미국 질병통제예방센터(CDC)에 따르면 매년 최대 4억 명이 뎅기열에 감염되는 것으로 추정됩니다. 이 중 약 1억 명이 감염으로 병에 걸리고, 4만 명이 중증 뎅기열로 사망합니다.
또한, 세계보건기구(WHO) 보고서에 따르면 매년 130만~400만 건의 콜레라 감염 사례가 발생하고, 전 세계적으로 2만 1천~14만 3천 명이 사망하는 것으로 추정됩니다. 콜레라는 심각한 급성 수양성 설사와 심각한 탈수를 유발하는 매우 위험한 질병으로 여겨집니다.
감염성 질환의 증가로 인해 항원에 대한 면역 반응을 유도하여 감염성 질환을 치료하는 치료용 백신에 대한 수요가 증가할 것입니다.

제약 요인
백신 개발에 대한 막대한 자본 지출, 연구 개발(R&D) 비용 상승, 더욱 복잡한 질병을 표적으로 하는 데 따른 생물학적 및 기술적 어려움, 더 나은 치료 표준과의 경쟁, 안전성과 효능을 입증하기 위한 대규모 임상 연구, 그리고 엄격한 규제는 예측 기간 동안 시장 성장을 저해할 것으로 예상되는 요인입니다.
세분화 분석
글로벌 치료용 백신 시장은 유형, 제품, 기술, 유통 채널 및 지역별로 세분화됩니다.
암 백신 부문은 시장 점유율의 38.3%를 차지했습니다.
모든 잠재적 항원을 면역 체계에 전달할 수 있다는 것이 암 백신의 가장 중요한 장점입니다. 동종 또는 자가 암 백신은 전체 세포 또는 세포 용해물에 방사선을 조사하여 생성하고 환자에게 투여할 수 있습니다.
암 백신 부문은 치료용 백신으로 치료할 수 있는 다양한 암의 수가 증가함에 따라 치료용 백신 시장에서 지배적인 위치를 차지하고 있으며, 이러한 추세는 예측 기간 동안 지속될 것으로 예상됩니다. 예를 들어, 미국 암 학회(American Society of Cancer)에 따르면 약 288,930건의 새로운 암 환자가 진단될 것으로 추정됩니다.
또한, 2023년에는 약 82,290건의 방광암과 97,610건의 흑색종이 새로 진단될 것으로 추정됩니다. 종양 세포 백신의 개발로 암 치료가 가능해짐에 따라, 암 발병률 증가가 해당 부문의 성장을 촉진할 것으로 예상됩니다.
지역 분석
북미는 세계 치료용 백신 시장에서 중요한 위치를 차지할 것으로 예상됩니다.
북미는 세계 치료용 백신 시장에서 지배적인 위치를 차지하고 있습니다. 만성 감염성 질환, 암, 알츠하이머병 발병률 증가는 시장 성장을 견인하는 요인이며, 이러한 추세는 예측 기간 동안 지속될 것으로 예상됩니다.
알츠하이머 샌디에이고 협회(Alzheimer's San Diego Organization)에 따르면, 미국에서는 67초마다 최소 한 명씩 알츠하이머병에 걸리는 것으로 추정됩니다. 2023년에는 약 50만 건의 새로운 알츠하이머병 사례가 진단될 것으로 추산됩니다.
또한 미국 암 학회에 따르면 약 8만 1,800건의 새로운 신장암 사례가 진단될 것으로 추산됩니다. 따라서 질병 발생 건수 증가로 치료용 백신 수요가 증가할 것으로 예상됩니다.
이러한 질병 발생 건수 증가는 치료용 백신에 대한 수요 증가로 이어질 것으로 보입니다.
또한 주요 제조업체의 존재, 제약 회사의 백신 개발 투자 증가, 정부의 적극적인 정책, 유리한 자회사, 그리고 방대한 환자 풀은 북미 시장 성장을 견인하고 있습니다.
코로나19 영향 분석
코로나19는 시장 성장에 긍정적인 영향을 미쳤습니다. 이 기간 동안 치료용 백신에 대한 수요가 증가했습니다. 코로나19 확진자 수 증가는 바이러스에 대한 항체를 생성하는 치료용 백신 생산의 시급성과 수요를 증가시켰습니다.

경쟁 환경
전 세계 치료용 백신 시장에서 상당한 시장 점유율을 차지하는 주요 기업으로는 Elicio Therapeutics, Argos Therapeutics, CSL Limited, Johnson & Johnson, AstraZeneca Plc, Merck & Co., Inc., Eli Lilly and Company, Sanofi, Dynavax Technologies, GSK Pharmaceuticals 등이 있습니다.
주요 개발 사항
• 2023년 1월 24일, 인도 세럼 연구소(SII)는 인도 최초의 자체 개발 자궁경부암 백신 'CERVAVAC'을 출시했습니다.

• 2023년 5월 11일, TechInvention Lifecare India는 한국의 Eubiologics Co.와 협력하여 경구용 콜레라 백신인 Euvichol-Plus를 인도에 출시했습니다.
보고서 구매 이유

• 유형, 제품, 기술, 유통 채널 및 지역별 글로벌 치료용 백신 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악하기 위해.

• 트렌드 분석 및 공동 개발을 통해 상업적 기회를 파악합니다.

• 모든 부문을 포함한 치료용 백신 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함한 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 치료용 백신 시장 보고서는 약 69개의 표, 70개의 그림, 183페이지 분량입니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Therapeutic Vaccines Market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.
Therapeutic vaccination is one that is taken after infection to induce antiviral immunity and thereby change the course of the disease. It’s ultimate goal is to change host immunity in order to eradicate disease and develop long-term memory.
The rapid advancement of nanobiotechnology has allowed for advancements in therapeutic cancer vaccinations. A therapeutic cancer vaccine's primary purpose is to elicit a cellular immune response, including the activation of killer T cells.
Market Dynamics: Drivers & Restraints
Increase in the prevalence of infectious diseases
The increase in infectious diseases has impacted the lives of a number of people. In order to prevent infections a number of new therapeutic vaccines have been introduced. The increase in innovations of therapeutic vaccines is expected to drive market growth.
For instance, according to the Centers for Disease Control (CDC), it is estimated that each year, up to 400 million people get infected with dengue. Approximately 100 million people get sick from infection, and 40,000 die from severe dengue.
Additionally, according to the report by World Health Organization (WHO), it is stated that researchers have estimated that every year, there are 1.3 to 4.0 million cases of cholera, and 21 000 to 143 000 deaths worldwide due to the infection. Cholera is considered an extremely serious disease that can cause severe acute watery diarrhea with severe dehydration.
The increase in the number of infectious diseases will increase the demand for therapeutic vaccines in order to treat infectious diseases by developing an immune response against the antigens present.
Restraint
Huge capital expenditure on vaccine development, the rising cost of research and development (R&D), biological and technical challenges associated with targeting more complex diseases, competition with better standards of care, the larger scale of clinical studies to prove safety and efficacy, and stringent regulations are the factors the market is expected to get hampered in the forecast period.
Segment Analysis
The global therapeutic vaccines market is segmented based on type, products, technology, distribution channel and region.
Cancer vaccines segment accounted for 38.3% of the market share
The ability to deliver all potential antigens to the immune system is the most essential advantage of cancer vaccines. Cancer vaccines, either allogeneic or autologous, can be created and delivered to patients using irradiation of whole cells or cell lysates.
Cancer vaccines segment has been holding a dominant segment in the therapeutic vaccines market due to the rise in the number of different cancers that can be treated through therapeutic vaccines. It is expected to continue throughout the forecast period. For instance, according to the American Society of Cancer, it is estimated that about 288,930 new cancer cases are to be diagnosed.
Additionally, it is estimated that about 82,290 new bladder cancer cases and 97,610 melanoma cases are to be diagnosed in the year 2023. The availability of tumor cell vaccines is expected to treat cancers. Thus, an increase in the incidence of cancer cases is expected to raise the growth of the segment.
Geographical Analysis
North America is expected to hold a significant position in the global therapeutic vaccines market share
North America is a dominant force in the global therapeutic vaccine market. The rising incidence of chronic infectious diseases, cancer, and Alzheimer’s, are the factors that are driving the market growth. It is expected to continue throughout the forecast period.
According to Alzheimer's San Diego Organization, it is estimated that at least one person in America develops Alzheimer's every 67 seconds. It is estimated that nearly 500,000 new cases of Alzheimer's disease will be diagnosed in 2023.
Additionally, according to the American Society of Cancer, it is estimated that about 81,800 new cases of kidney cancer will be diagnosed. Thus, an increase in disease conditions is expected to increase the demand for therapeutic vaccines.
Also, the presence of key manufacturers, increasing investments by pharmaceutical companies for vaccine development in the region, proactive government initiatives, favorable subsidiaries, and a large patient pool are driving the market in North America.
COVID-19 Impact Analysis
COVID-19 has impacted the growth of the market positively. There is a rise in the demand for therapeutic vaccines during this period. The increase in the cases of COVID-19 has increased the emergency and demand for the production of therapeutic vaccines which have the ability to produce antibodies against the virus.
Competitive Landscape
The leading companies with a significant market share in global therapeutic vaccines include Elicio Therapeutics, Argos Therapeutics, CSL Limited, Johnson & Johnson, AstraZeneca Plc, Merck & Co., Inc., Eli Lilly and Company, Sanofi, Dynavax Technologies., and GSK Pharmaceuticals among others.
Key Developments
• On January 24, 2023, the Serum Institute of India (SII) launched India's First Indigenously Made Cervical Cancer Vaccine 'CERVAVAC'.
• On May 11, 2023, TechInvention Lifecare India in partnership with Eubiologics Co, South Korea, launched Euvichol-Plus, an oral cholera vaccine in India.
Why Purchase the Report?
• To visualize the global therapeutic vaccines market segmentation based on type, products, technology, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of therapeutic vaccines market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global therapeutic vaccines market report would provide approximately 69 tables, 70 figures, and 183 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

Table of Contents
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Products
3.3. Snippet by Technology
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increase in the prevalence of infectious diseases
4.1.1.2. YY
4.1.2. Restraints
4.1.2.1. High investments in manufacturing
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Antigen Vaccines *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Dendritic Cell Vaccine
7.4. DNA Vaccine
7.5. Tumor Cell Vaccines
8. By Products
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products
8.1.2. Market Attractiveness Index, By Products
8.2. Autoimmune Disease Vaccine *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Addiction Vaccine
8.4. Cancer Vaccines
8.5. Neurological Disease Vaccine
8.6. Infectious Disease Vaccine
8.7. Others
9. By Technology
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
9.1.2. Market Attractiveness Index, By Technology
9.2. Autologous Vaccines *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Allogeneic Vaccines
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies *
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacies
10.4. Online Pharmacies
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Elicio Therapeutics *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Argos Therapeutics
13.3. CSL Limited
13.4. Johnson & Johnson
13.5. AstraZeneca Plc
13.6. Merck & Co., Inc.,
13.7. Eli Lilly and Company
13.8. Sanofi
13.9. Dynavax Technologies.
13.10. GSK Pharmaceuticals
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Elicio Therapeutics, 4. Key Developments, Argos Therapeutics, CSL Limited, Johnson & Johnson, AstraZeneca Plc, Merck & Co., Inc.,, Eli Lilly and Company, Sanofi, Dynavax Technologies., GSK Pharmaceuticals

표 목록 (Tables)

List of Tables

Table 1 Global Therapeutic Vaccines Market Value, By Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Therapeutic Vaccines Market Value, By Products, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Therapeutic Vaccines Market Value, By Technology, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Therapeutic Vaccines Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Therapeutic Vaccines Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Therapeutic Vaccines Market Value, By Type, 2023, 2027 & 2031 (US$ Million)

Table 7 Global Therapeutic Vaccines Market Value, By Type, 2022-2031 (US$ Million)

Table 8 Global Therapeutic Vaccines Market Value, By Products, 2023, 2027 & 2031 (US$ Million)

Table 9 Global Therapeutic Vaccines Market Value, By Products, 2022-2031 (US$ Million)

Table 10 Global Therapeutic Vaccines Market Value, By Technology, 2023, 2027 & 2031 (US$ Million)

Table 11 Global Therapeutic Vaccines Market Value, By Technology, 2022-2031 (US$ Million)

Table 12 Global Therapeutic Vaccines Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 13 Global Therapeutic Vaccines Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 14 Global Therapeutic Vaccines Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 15 Global Therapeutic Vaccines Market Value, By Region, 2022-2031 (US$ Million)

Table 16 North America Therapeutic Vaccines Market Value, By Type, 2022-2031 (US$ Million)

Table 17 North America Therapeutic Vaccines Market Value, By Products, 2022-2031 (US$ Million)

Table 18 North America Therapeutic Vaccines Market Value, By Technology, 2022-2031 (US$ Million)

Table 19 North America Therapeutic Vaccines Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 20 North America Therapeutic Vaccines Market Value, By Country, 2022-2031 (US$ Million)

Table 21 South America Therapeutic Vaccines Market Value, By Type, 2022-2031 (US$ Million)

Table 22 South America Therapeutic Vaccines Market Value, By Products, 2022-2031 (US$ Million)

Table 23 South America Therapeutic Vaccines Market Value, By Technology, 2022-2031 (US$ Million)

Table 24 South America Therapeutic Vaccines Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 25 South America Therapeutic Vaccines Market Value, By Country, 2022-2031 (US$ Million)

Table 26 Europe Therapeutic Vaccines Market Value, By Type, 2022-2031 (US$ Million)

Table 27 Europe Therapeutic Vaccines Market Value, By Products, 2022-2031 (US$ Million)

Table 28 Europe Therapeutic Vaccines Market Value, By Technology, 2022-2031 (US$ Million)

Table 29 Europe Therapeutic Vaccines Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 30 Europe Therapeutic Vaccines Market Value, By Country, 2022-2031 (US$ Million)

Table 31 Asia-Pacific Therapeutic Vaccines Market Value, By Type, 2022-2031 (US$ Million)

Table 32 Asia-Pacific Therapeutic Vaccines Market Value, By Products, 2022-2031 (US$ Million)

Table 33 Asia-Pacific Therapeutic Vaccines Market Value, By Technology, 2022-2031 (US$ Million)

Table 34 Asia-Pacific Therapeutic Vaccines Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 35 Asia-Pacific Therapeutic Vaccines Market Value, By Country, 2022-2031 (US$ Million)

Table 36 Middle East & Africa Therapeutic Vaccines Market Value, By Type, 2022-2031 (US$ Million)

Table 37 Middle East & Africa Therapeutic Vaccines Market Value, By Products, 2022-2031 (US$ Million)

Table 38 Middle East & Africa Therapeutic Vaccines Market Value, By Technology, 2022-2031 (US$ Million)

Table 39 Middle East & Africa Therapeutic Vaccines Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 40 Elicio Therapeutics: Overview

Table 41 Elicio Therapeutics: Product Portfolio

Table 42 Elicio Therapeutics: Key Developments

Table 43 Argos Therapeutics: Overview

Table 44 Argos Therapeutics: Product Portfolio

Table 45 Argos Therapeutics: Key Developments

Table 46 CSL Limited: Overview

Table 47 CSL Limited: Product Portfolio

Table 48 CSL Limited: Key Developments

Table 49 Johnson & Johnson: Overview

Table 50 Johnson & Johnson: Product Portfolio

Table 51 Johnson & Johnson: Key Developments

Table 52 AstraZeneca Plc: Overview

Table 53 AstraZeneca Plc: Product Portfolio

Table 54 AstraZeneca Plc: Key Developments

Table 55 Merck & Co., Inc.: Overview

Table 56 Merck & Co., Inc.: Product Portfolio

Table 57 Merck & Co., Inc.: Key Developments

Table 58 Eli Lilly and Company: Overview

Table 59 Eli Lilly and Company: Product Portfolio

Table 60 Eli Lilly and Company: Key Developments

Table 61 Sanofi: Overview

Table 62 Sanofi: Product Portfolio

Table 63 Sanofi: Key Developments

Table 64 Dynavax Technologies.: Overview

Table 65 Dynavax Technologies.: Product Portfolio

Table 66 Dynavax Technologies.: Key Developments

Table 67 GSK Pharmaceuticals: Overview

Table 68 GSK Pharmaceuticals: Product Portfolio

Table 69 GSK Pharmaceuticals: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Therapeutic Vaccines Market Value, 2022-2031 (US$ Million)

Figure 2 Global Therapeutic Vaccines Market Share, By Type, 2022 & 2031 (%)

Figure 3 Global Therapeutic Vaccines Market Share, By Products, 2022 & 2031 (%)

Figure 4 Global Therapeutic Vaccines Market Share, By Technology, 2022 & 2031 (%)

Figure 5 Global Therapeutic Vaccines Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 6 Global Therapeutic Vaccines Market Share, By Region, 2022 & 2031 (%)

Figure 7 Global Therapeutic Vaccines Market Y-o-Y Growth, By Type, 2022-2030 (%)

Figure 8 Antigen Vaccines Therapeutic Vaccines Market Value, 2022-2031 (US$ Million)

Figure 9 Dendritic Cell Vaccine Therapeutic Vaccines Market Value, 2022-2031 (US$ Million)

Figure 10 DNA Vaccine Therapeutic Vaccines Market Value, 2022-2031 (US$ Million)

Figure 11 Tumor Cell Vaccines Therapeutic Vaccines Market Value, 2022-2031 (US$ Million)

Figure 12 Global Therapeutic Vaccines Market Y-o-Y Growth, By Products, 2022-2030 (%)

Figure 13 Autoimmune Disease Vaccine Products in Global Therapeutic Vaccines Market Value, 2022-2031 (US$ Million)

Figure 14 Addiction Vaccine Products in Global Therapeutic Vaccines Market Value, 2022-2031 (US$ Million)

Figure 15 Cancer Vaccines Products in Global Therapeutic Vaccines Market Value, 2022-2031 (US$ Million)

Figure 16 Neurological Disease Vaccine Products in Global Therapeutic Vaccines Market Value, 2022-2031 (US$ Million)

Figure 17 Infectious Disease Vaccine Products in Global Therapeutic Vaccines Market Value, 2022-2031 (US$ Million)

Figure 18 Others Products in Global Therapeutic Vaccines Market Value, 2022-2031 (US$ Million)

Figure 19 Global Therapeutic Vaccines Market Y-o-Y Growth, By Technology, 2022-2030 (%)

Figure 20 Autologous Vaccines Technology in Global Therapeutic Vaccines Market Value, 2022-2031 (US$ Million)

Figure 21 Allogeneic Vaccines Technology in Global Therapeutic Vaccines Market Value, 2022-2031 (US$ Million)

Figure 22 Global Therapeutic Vaccines Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 23 Hospital Pharmacies Distribution Channel in Global Therapeutic Vaccines Market Value, 2022-2031 (US$ Million)

Figure 24 Retail Pharmacies Distribution Channel in Global Therapeutic Vaccines Market Value, 2022-2031 (US$ Million)

Figure 25 Online Pharmacies Distribution Channel in Global Therapeutic Vaccines Market Value, 2022-2031 (US$ Million)

Figure 26 Global Therapeutic Vaccines Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 27 North America Therapeutic Vaccines Market Value, 2022-2031 (US$ Million)

Figure 28 Asia-Pacific Therapeutic Vaccines Market Value, 2022-2031 (US$ Million)

Figure 29 Europe Therapeutic Vaccines Market Value, 2022-2031 (US$ Million)

Figure 30 South America Therapeutic Vaccines Market Value, 2022-2031 (US$ Million)

Figure 31 Middle East and Africa Therapeutic Vaccines Market Value, 2022-2031 (US$ Million)

Figure 32 North America Therapeutic Vaccines Market Value, 2022-2031 (US$ Million)

Figure 33 North America Therapeutic Vaccines Market Share, By Type, 2022 & 2031 (%)

Figure 34 North America Therapeutic Vaccines Market Share, By Products, 2022 & 2031 (%)

Figure 35 North America Therapeutic Vaccines Market Share, By Technology, 2022 & 2031 (%)

Figure 36 North America Therapeutic Vaccines Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 37 North America Therapeutic Vaccines Market Share, By Country, 2022 & 2031 (%)

Figure 38 South America Therapeutic Vaccines Market Value, 2022-2031 (US$ Million)

Figure 39 South America Therapeutic Vaccines Market Share, By Type, 2022 & 2031 (%)

Figure 40 South America Therapeutic Vaccines Market Share, By Products, 2022 & 2031 (%)

Figure 41 South America Therapeutic Vaccines Market Share, By Technology, 2022 & 2031 (%)

Figure 42 South America Therapeutic Vaccines Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 43 South America Therapeutic Vaccines Market Share, By Country, 2022 & 2031 (%)

Figure 44 Europe Therapeutic Vaccines Market Value, 2022-2031 (US$ Million)

Figure 45 Europe Therapeutic Vaccines Market Share, By Type, 2022 & 2031 (%)

Figure 46 Europe Therapeutic Vaccines Market Share, By Products, 2022 & 2031 (%)

Figure 47 Europe Therapeutic Vaccines Market Share, By Technology, 2022 & 2031 (%)

Figure 48 Europe Therapeutic Vaccines Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 49 Europe Therapeutic Vaccines Market Share, By Country, 2022 & 2031 (%)

Figure 50 Asia-Pacific Therapeutic Vaccines Market Value, 2022-2031 (US$ Million)

Figure 51 Asia-Pacific Therapeutic Vaccines Market Share, By Type, 2022 & 2031 (%)

Figure 52 Asia-Pacific Therapeutic Vaccines Market Share, By Products, 2022 & 2031 (%)

Figure 53 Asia-Pacific Therapeutic Vaccines Market Share, By Technology, 2022 & 2031 (%)

Figure 54 Asia-Pacific Therapeutic Vaccines Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 55 Asia-Pacific Therapeutic Vaccines Market Share, By Country, 2022 & 2031 (%)

Figure 56 Middle East & Africa Therapeutic Vaccines Market Value, 2022-2031 (US$ Million)

Figure 57 Middle East & Africa Therapeutic Vaccines Market Share, By Type, 2022 & 2031 (%)

Figure 58 Middle East & Africa Therapeutic Vaccines Market Share, By Products, 2022 & 2031 (%)

Figure 59 Middle East & Africa Therapeutic Vaccines Market Share, By Technology, 2022 & 2031 (%)

Figure 60 Middle East & Africa Therapeutic Vaccines Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 61 Elicio Therapeutics: Financials

Figure 62 Argos Therapeutics: Financials

Figure 63 CSL Limited: Financials

Figure 64 Johnson & Johnson: Financials

Figure 65 AstraZeneca Plc: Financials

Figure 66 Merck & Co., Inc.: Financials

Figure 67 Eli Lilly and Company: Financials

Figure 68 Sanofi: Financials

Figure 69 Dynavax Technologies.: Financials

Figure 70 GSK Pharmaceuticals: Financials

글로벌 치료용 백신 시장 – 2023년~2030년

Global Therapeutic Vaccines Market - 2023 -2030